---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-157839"
form_type: "8-K"
ticker: "CNTA"
cik: "0001847903"
company_name: "Centessa Pharmaceuticals plc"
filed_at: "2024-06-10T23:59:59+00:00"
generated_at: "2026-06-01T05:22:49.932908+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Centessa appoints John Crowley as CFO, Gregory Weinhoff as Chief Business Officer

## Summary
- John Crowley appointed CFO effective June 10, 2024; replaces Gregory Weinhoff who becomes CBO.
- Crowley receives $525k base salary, 40% target annual bonus, and option to purchase 600,000 ADSs.
- Crowley previously CFO of Fusion Pharmaceuticals (acquired by AstraZeneca) and Merus, plus finance roles at Charles River, Ironwood, Vertex.
- Weinhoff moves from CFO to newly created CBO role; he co-founded Arvelle Therapeutics and led in-licensing of cenobamate.
- No family relationships or related-party transactions disclosed between Crowley and the company.

## SEC filing metadata
- accession: 0001193125-24-157839
- form_type: 8-K
- ticker: CNTA
- cik: 0001847903
- company_name: Centessa Pharmaceuticals plc
- filed_at: 2024-06-10T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1847903/000119312524157839/0001193125-24-157839-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1847903/000119312524157839/d793909d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-157839
- JSON: https://secwatch.observer/filing/0001193125-24-157839.json
- Plain text: https://secwatch.observer/filing/0001193125-24-157839.txt

## Key facts
- Executive change
  John Crowley was appointed as Chief Financial Officer at Centessa Pharmaceuticals plc.
  - Action: appointed
  - Role: Chief Financial Officer
  source text: On June 10, 2024, Centessa Pharmaceuticals plc (the “Company”) announced the appointment of John Crowley as Chief Financial Officer, which was approved by the Board of Directors of the Company on June 5, 2024, effective June 10, 2024 (the “Start Date”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1847903/000119312524157839/0001193125-24-157839-index.htm
- Executive change
  Gregory Weinhoff was appointed as Chief Business Officer at Centessa Pharmaceuticals plc.
  - Action: appointed
  - Role: Chief Business Officer
  source text: On June 10, 2024, the Company also announced that the Board has appointed Dr. Gregory Weinhoff as the Company’s Chief Business Officer, on June 5, 2024, effective on the Start Date.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1847903/000119312524157839/0001193125-24-157839-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.